SpringerLink
Log in

Renal Hypophosphatemia

  • Living reference work entry
  • First Online:
Pediatric Nephrology

  • 41 Accesses

Abstract

Over the last decade, research in the field of genetic disorders resulting in hypophosphatemia has significantly broadened our understanding of phosphate metabolism. X-linked hypophosphatemia is the most common inherited form of rickets, which is caused by renal phosphate wasting. The common denominator for all types of rickets is hypophosphatemia, which leads to an insufficient supply of the mineral to the growing bone. Recent findings on disease mechanisms and the role of fibroblast growth factor 23 (FGF23) in hypophosphatemic diseases have opened up new therapeutic avenues such as FGF23 blockade. We will discuss the genetic and clinical features of hypophosphatemic disorders and provide understanding and treatment options based on recent guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Winters RW, Graham JB, Williams TF, McFalls VW, Burnett CH. A genetic study of familial hypophosphatemia and vitamin D resistant rickets with a review of the literature. 1958. Medicine (Baltimore). 1991;70(3):215–7.

    Article  CAS  Google Scholar 

  2. Marcucci G, Masi L, Ferrarì S, Haffner D, Javaid MK, Kamenický P, et al. Phosphate wasting disorders in adults. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2018;29(11):2369–87.

    Article  CAS  Google Scholar 

  3. Carpenter TO, Shaw NJ, Portale AA, Ward LM, Abrams SA, Pettifor JM. Rickets Nat Rev Dis Primer. 2017;3:17101.

    Article  Google Scholar 

  4. Tiosano D, Hochberg Z. Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab. 2009;27(4):392–401.

    Article  PubMed  Google Scholar 

  5. Goretti Penido M, Alon US. Phosphate homeostasis and its role in bone health. Pediatr Nephrol Berl Ger. 2012;27(11):2039–48.

    Article  Google Scholar 

  6. Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019;14(1):58.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zheng B, Wang C, Chen Q, Che R, Sha Y, Zhao F, et al. Functional characterization of PHEX gene variants in children with X-linked hypophosphatemic rickets shows no evidence of genotype-phenotype correlation. J Bone Miner Res Off J Am Soc Bone Miner Res. 2020;35(9):1718–25.

    Article  CAS  Google Scholar 

  8. Gaucher C, Walrant-Debray O, Nguyen TM, Esterle L, Garabedian M, Jehan F. PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. Hum Genet. 2009;125(4):401–11.

    Article  PubMed  Google Scholar 

  9. gene A. (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP consortium. Nat Genet. 1995;11(2):130–6.

    Article  Google Scholar 

  10. Beck-Nielsen SS, Brixen K, Gram J, Brusgaard K. Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets. J Hum Genet. 2012;57(7):453–8.

    Article  CAS  PubMed  Google Scholar 

  11. Biber J, Hernando N, Forster I. Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535–50.

    Article  CAS  PubMed  Google Scholar 

  12. Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, Bastepe M, Abu-Zahra H, et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet. 2006;78(2):179–92.

    Article  CAS  PubMed  Google Scholar 

  13. Huqun Null, Izumi S, Miyazawa H, Ishii K, Uchiyama B, Ishida T, et al. Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med 2007;175(3):263–8.

    Google Scholar 

  14. Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kido S, Miyamoto K, Mizobuchi H, Taketani Y, Ohkido I, Ogawa N, et al. Identification of regulatory sequences and binding proteins in the type II sodium/phosphate cotransporter NPT2 gene responsive to dietary phosphate. J Biol Chem. 1999;274(40):28256–63.

    Article  CAS  PubMed  Google Scholar 

  16. Murer H, Biber J. Molecular mechanisms of renal apical Na/phosphate cotransport. Annu Rev Physiol. 1996;58:607–18.

    Article  CAS  PubMed  Google Scholar 

  17. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2011;26(7):1381–8.

    Article  Google Scholar 

  18. Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;

    Google Scholar 

  19. Rothenbuhler A, Fadel N, Debza Y, Bacchetta J, Diallo MT, Adamsbaum C, et al. High incidence of cranial synostosis and Chiari I malformation in children with X-Linked Hypophosphatemic Rickets (XLHR). J Bone Miner Res. 2019;34(3):490–6.

    Article  CAS  PubMed  Google Scholar 

  20. Chaussain-Miller C, Sinding C, Wolikow M, Lasfargues J-J, Godeau G, Garabédian M. Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D. J Pediatr. 2003;142(3):324–31.

    Article  CAS  PubMed  Google Scholar 

  21. Lempicki M, Rothenbuhler A, Merzoug V, Franchi-Abella S, Chaussain C, Adamsbaum C, et al. Magnetic resonance imaging features as surrogate markers of X-linked Hypophosphatemic rickets activity. Horm Res Paediatr. 2017;87(4):244–53.

    Article  CAS  PubMed  Google Scholar 

  22. Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3(1):R13–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Thacher TD, Fischer PR, Pettifor JM, Lawson JO, Manaster BJ, Reading JC. Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr. 2000;46(3):132–9.

    Article  CAS  PubMed  Google Scholar 

  24. Ewert A, Leifheit-Nestler M, Hohenfellner K, Büscher A, Kemper MJ, Oh J, et al. Bone and mineral metabolism in children with nephropathic cystinosis compared with other CKD Entities. J Clin Endocrinol Metab. 2020;105(8)

    Google Scholar 

  25. Fischer D-C, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G, et al. Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem. 2012;49(Pt 6):546–53.

    Article  CAS  PubMed  Google Scholar 

  26. Haffner D, Nissel R, Wuhl E, Mehls O. Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics. 2004;113(6):e593–6.

    Article  PubMed  Google Scholar 

  27. Biosse Duplan M, Coyac BR, Bardet C, Zadikian C, Rothenbuhler A, Kamenicky P, et al. Phosphate and vitamin D prevent periodontitis in X-linked hypophosphatemia. J Dent Res. 2017;96(4):388–95.

    Article  CAS  PubMed  Google Scholar 

  28. Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab. 2010;95(11):E352–7.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone. 2008;42(6):1235–9.

    Article  CAS  PubMed  Google Scholar 

  30. Bianchine JW, Stambler AA, Harrison HE. Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser. 1971;7(6):287–95.

    CAS  PubMed  Google Scholar 

  31. Gribaa M, Younes M, Bouyacoub Y, Korbaa W, Ben Charfeddine I, Touzi M, et al. An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab. 2010;28(1):111–5.

    Article  PubMed  Google Scholar 

  32. Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab. 1997;82(2):674–81.

    Article  CAS  PubMed  Google Scholar 

  33. Kruse K, Woelfel D, Strom TM, Storm TM. Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Horm Res. 2001;55(6):305–8.

    CAS  PubMed  Google Scholar 

  34. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011;108(46):E1146–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011;96(11):3541–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Imel EA, Biggin A, Schindeler A, Munns CF. FGF23, hypophosphatemia, and emerging treatments. JBMR Plus. 2019;3(8):e10190.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Perry W, Stamp TC. Hereditary hypophosphataemic rickets with autosomal recessive inheritance and severe osteosclerosis. A report of two cases. J Bone Joint Surg Br. 1978;60-B(3):430–4.

    Article  CAS  PubMed  Google Scholar 

  38. Feng JQ, Ward LM, Liu S, Lu Y, **e Y, Yuan B, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38(11):1310–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, Amyere M, Wagenstaller J, Müller-Barth U, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38(11):1248–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Lorenz-Depiereux B, Schnabel D, Tiosano D, Häusler G, Strom TM. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet. 2010;86(2):267–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet. 2010;86(2):273–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, et al. Mutations in ENPP1 are associated with « idiopathic » infantile arterial calcification. Nat Genet. 2003;34(4):379–81.

    Article  CAS  PubMed  Google Scholar 

  43. Kotwal A, Ferrer A, Kumar R, Singh RJ, Murthy V, Schultz-Rogers L, et al. Clinical and biochemical phenotypes in a family with ENPP1 mutations. J Bone Miner Res. 2020;35(4):662–70.

    Article  CAS  PubMed  Google Scholar 

  44. Rafaelsen SH, Raeder H, Fagerheim AK, Knappskog P, Carpenter TO, Johansson S, et al. Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification. J Bone Miner Res. 2013;28(6):1378–85.

    Article  CAS  PubMed  Google Scholar 

  45. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348(17):1656–63.

    Article  CAS  PubMed  Google Scholar 

  47. Carpenter TO, Miller PD, Weber TJ, Peacock M, Insogna KL, Kumar R, et al. OR29-06 burosumab improves biochemical, skeletal, and clinical features of tumor-induced osteomalacia syndrome. J Endocr Soc. 2020;4(Suppl 1) Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208350/

  48. Brownstein CA, Adler F, Nelson-Williams C, Iijima J, Li P, Imura A, et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A. 2008;105(9):3455–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112(5):683–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Lim YH, Ovejero D, Sugarman JS, Deklotz CM, Maruri A, Eichenfield LF, et al. Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet. 2014;23(2):397–407.

    Article  CAS  PubMed  Google Scholar 

  51. Tieder M, Modai D, Samuel R, Arie R, Halabe A, Bab I, et al. Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med. 1985;312(10):611–7.

    Article  CAS  PubMed  Google Scholar 

  52. Jaureguiberry G, Carpenter TO, Forman S, Jüppner H, Bergwitz C. A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. Am J Physiol Ren Physiol. 2008;295(2):F371–9.

    Article  CAS  Google Scholar 

  53. Dasgupta D, Wee MJ, Reyes M, Li Y, Simm PJ, Sharma A, et al. Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J Am Soc Nephrol JASN. 2014;25(10):2366–75.

    Article  CAS  PubMed  Google Scholar 

  54. Segawa H, Kaneko I, Takahashi A, Kuwahata M, Ito M, Ohkido I, et al. Growth-related renal type II Na/pi cotransporter. J Biol Chem. 2002;277(22):19665–72.

    Article  CAS  PubMed  Google Scholar 

  55. Ma Y, Lv H, Wang J, Tan J. Heterozygous mutation of SLC34A1 in patients with hypophosphatemic kidney stones and osteoporosis: a case report. J Int Med Res. 2020;48(3):300060519896146.

    PubMed  Google Scholar 

  56. Marzin P, Baujat G, Gensburger D, Huber C, Bole C, Panuel M, et al. Heterozygous FGFR1 mutation may be responsible for an incomplete form of osteoglophonic dysplasia, characterized only by radiolucent bone lesions and teeth retentions. Eur J Med Genet. 2020;63(2):103729.

    Article  PubMed  Google Scholar 

  57. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet. 2005;76(2):361–7.

    Article  CAS  PubMed  Google Scholar 

  58. Prié D, Huart V, Bakouh N, Planelles G, Dellis O, Gérard B, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med. 2002;347(13):983–91.

    Article  PubMed  Google Scholar 

  59. Kooijmans EC, Bökenkamp A, Tjahjadi NS, Tettero JM, van Dulmen-den Broeder E, van der Pal HJ, et al. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev. 2019;3:CD008944.

    PubMed  Google Scholar 

  60. Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, et al. Long-term evaluation of Ifosfamide-related nephrotoxicity in children. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(32):5350–5.

    Article  CAS  Google Scholar 

  61. Saeedi R, Jiang SY, Holmes DT, Kendler DL. Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia. Calcif Tissue Int. 2014;94(6):665–8.

    Article  CAS  PubMed  Google Scholar 

  62. Gizard A, Rothenbuhler A, Pe** Z, Finidori G, Glorion C, de Billy B, et al. Outcomes of orthopedic surgery in a cohort of 49 patients with X-linked hypophosphatemic rickets (XLHR). Endocr Connect. 2017;6(8):566–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Lecoq A-L, Brandi ML, Linglart A, Kamenický P. Management of X-linked hypophosphatemia in adults. Metabolism. 2020;103S:154049.

    Article  PubMed  CAS  Google Scholar 

  64. Carpenter TO, Whyte MP, Imel EA, Boot AM, Högler W, Linglart A, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378(21):1987–98.

    Article  CAS  PubMed  Google Scholar 

  65. Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, et al. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7(3):189–99.

    Article  PubMed  Google Scholar 

  66. Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet Lond Engl. 2019;393(10189):2416–27.

    Article  CAS  Google Scholar 

  67. Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab. 2015;100(7):2565–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Ruppe MD, Zhang X, Imel EA, Weber TJ, Klausner MA, Ito T, et al. Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep. 2016;5:158–62.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of Burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res Off J Am Soc Bone Miner Res. 2018;

    Google Scholar 

  70. Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, et al. Continued beneficial effects of Burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int. 2019;105(3):271–84.

    Article  CAS  PubMed  Google Scholar 

  71. Insogna KL, Rauch F, Kamenický P, Ito N, Kubota T, Nakamura A, et al. Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 2019;34(12):2183–91.

    Article  CAS  Google Scholar 

  72. Emma F, Haffner D. FGF23 blockade coming to clinical practice. Kidney Int. 2018;94(5):846–8.

    Article  PubMed  Google Scholar 

  73. Wilson DM, Lee PD, Morris AH, Reiter EO, Gertner JM, Marcus R, et al. Growth hormone therapy in hypophosphatemic rickets. Am J Dis Child. 1991;145(10):1165–70.

    CAS  PubMed  Google Scholar 

  74. Živičnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R, et al. Three-year growth hormone treatment in short children with X-linked Hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab. 2011;96(12):E2097–105.

    Article  PubMed  CAS  Google Scholar 

  75. Meyerhoff N, Haffner D, Staude H, Wühl E, Marx M, Beetz R, et al. Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets. Pediatr Nephrol Berl Ger. 2018;33(3):447–56.

    Article  Google Scholar 

  76. Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr. 2001;138(2):236–43.

    Article  CAS  PubMed  Google Scholar 

  77. Yavropoulou MP, Kotsa K, Gotzamani Psarrakou A, Papazisi A, Tranga T, Ventis S, et al. Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. Horm Athens Greece. 2010;9(3):274–8.

    Article  Google Scholar 

  78. Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol. 2008;3(3):658–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS, Collins MT. Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2007;22(6):931–7.

    Article  CAS  Google Scholar 

  80. Leifheit-Nestler M, Kucka J, Yoshizawa E, Behets G, D’Haese P, Bergen C, et al. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia. Bone. 2017;103:224–32.

    Article  CAS  PubMed  Google Scholar 

  81. Chaussain-Miller C, Sinding C, Septier D, Wolikow M, Goldberg M, Garabedian M. Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. Oral Dis. 2007;13(5):482–9.

    Article  CAS  PubMed  Google Scholar 

  82. Mao M, Carpenter TO, Whyte MP, Skrinar A, Chen C-Y, San Martin J, et al. Growth curves for children with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2020;105(10)

    Google Scholar 

  83. Cagnoli M, Richter R, Böhm P, Knye K, Empting S, Mohnike K. Spontaneous growth and effect of early therapy with calcitriol and phosphate in X-linked Hypophosphatemic rickets. Pediatr Endocrinol Rev PER. 2017;15(Suppl 1):119–22.

    PubMed  Google Scholar 

  84. Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K, Brock-Jacobsen B, Poulsen MR, et al. Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int. 2010;87(2):108–19.

    Article  CAS  PubMed  Google Scholar 

  85. Kruse K, Hinkel GK, Griefahn B. Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets. Eur J Pediatr. 1998;157(11):894–900.

    Article  CAS  PubMed  Google Scholar 

  86. Mäkitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2003;88(8):3591–7.

    Article  PubMed  CAS  Google Scholar 

  87. Quinlan C, Guegan K, Offiah A, Neill RO, Hiorns MP, Ellard S, et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol Berl Ger. 2012;27(4):581–8.

    Article  Google Scholar 

  88. Zivicnjak M, Schnabel D, Billing H, Staude H, Filler G, Querfeld U, et al. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol. 2011;26(2):223–31.

    Article  PubMed  Google Scholar 

  89. Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, et al. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3(7):1321–34.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174(3):325–33.

    Article  CAS  PubMed  Google Scholar 

  91. Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, et al. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis. 2018;

    Google Scholar 

  92. Lo SH, Lachmann R, Williams A, Piglowska N, Lloyd AJ. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. Qual Life Res Int J Qual Life Asp Treat Care Rehab. 2020;29(7):1883–93.

    CAS  Google Scholar 

  93. Greene WB. Genu varum and genu valgum in children: differential diagnosis and guidelines for evaluation. Compr Ther. 1996;22(1):22–9.

    CAS  PubMed  Google Scholar 

  94. Mäkitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2003;88(8):3591–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Kidney, Liver and Metabolic Diseases, Center for Rare Kidney Diseases, Hannover Medical School, Hannover, Germany

    Dieter Haffner

  2. AP-HP, Reference Center for Rare Disorders of the Calcium and Phosphate Metabolism, Filière OSCAR and Platform of expertise for rare diseases Paris-Sud, Université de Paris Saclay, Saint-Aubin, France

    Agnes Linglart

  3. Department of Endocrinology and Diabetology for children and Department of Adolescent Medicine, Bicêtre Paris-Saclay Hospital, Le Kremlin-Bicêtre, France

    Agnes Linglart

Authors
  1. Dieter Haffner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Agnes Linglart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dieter Haffner .

Editor information

Editors and Affiliations

  1. Division of Nephrology, Bambino Gesù Children’s Hospital –, ROMA, Roma, Italy

    Francesco Emma

  2. Division of Nephrology and Hypertension The Heart Institute, University of Cincinnati Cincinnati Children’s Hospital Medical C, Cincinnati, OH, USA

    Stuart Goldstein

  3. Division of Nephrology, All India Institute of Medical Sciences, Ansari Nagar East, Delhi, India

    Arvind Bagga

  4. Division of Pediatric Nephrology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

    Carlton M. Bates

  5. Renal Unit, Graet Ormond Street Hospital, London, UK

    Rukshana Shroff

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Germany, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Haffner, D., Linglart, A. (2021). Renal Hypophosphatemia. In: Emma, F., Goldstein, S., Bagga, A., Bates, C.M., Shroff, R. (eds) Pediatric Nephrology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27843-3_107-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-27843-3_107-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-27843-3

  • Online ISBN: 978-3-642-27843-3

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation